Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016

Antimicrob Agents Chemother. 2017 Aug 24;61(9):e01043-17. doi: 10.1128/AAC.01043-17. Print 2017 Sep.

Abstract

We evaluated trends in Staphylococcus aureus antimicrobial susceptibility in U.S. hospitals in the 2010-2016 period. A total of 21,056 clinical isolates from 42 medical centers were tested for susceptibility by broth microdilution methods. Methicillin-resistant S. aureus (MRSA) rates decreased from 50.0% (in 2010) to 42.2% (in 2016). Susceptibility to erythromycin, levofloxacin, and clindamycin increased slightly, whereas susceptibility to ceftaroline, trimethoprim-sulfamethoxazole, and tetracycline remained stable. Ceftaroline retained potent activity against methicillin-susceptible S. aureus (MSSA) and MRSA (97.2% susceptible) with no marked variations.

Keywords: MRSA; ceftaroline; cephalosporin; methicillin-resistant Staphylococcus aureus; skin and skin structure infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Ceftaroline
  • Cephalosporins / therapeutic use*
  • Clindamycin / therapeutic use
  • Erythromycin / therapeutic use
  • Humans
  • Levofloxacin / therapeutic use
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Methicillin-Resistant Staphylococcus aureus / isolation & purification
  • Microbial Sensitivity Tests / trends
  • Staphylococcal Skin Infections / drug therapy*
  • Staphylococcal Skin Infections / microbiology
  • Tetracycline / therapeutic use
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • United States

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Clindamycin
  • Erythromycin
  • Levofloxacin
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Tetracycline